This article summarizes the principal publications and those evidence-based clinical trials on dyslipidemias, including their main findings and recommendations for practicing cardiologists and clinicians. Emphasis is given to the confirmed data regarding the pathophysiology as well as the diagnoses of dyslipidemias, and the established therapeutic approaches validated in multiple well supervised control trials. The basic recommendations provided by the American Heart Association and the American College of Cardiology are presented as well as a brief description of the objectives, findings and results of the most recognized control trials, particularly those whose results have been published from 2000 to 2008. The importance of aggressive therapy to reach target lipids goals other than LDL-cholesterol in mixed dyslipidemias with combination therapy is strongly pointed out and emphasized.
Download full-text PDF |
Source |
---|
J Clin Med
January 2025
Department of Medicine, Division of Nephrology, Northwell Health, Staten Island University Hospital, Staten Island, NY 10305, USA.
: Lipid disorders are very prevalent in patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), leading to heightened cardiovascular risk. This review examines the effectiveness of lipid-lowering agents in these populations and explores gaps in the current research. The goal of this review is to assess the efficacy of lipid-lowering therapies in CKD and ESRD patients and identify future research needs.
View Article and Find Full Text PDFMusculoskeletal Care
March 2025
Department of Clinical Sciences, Clinical Epidemiology Unit, Orthopaedics, Lund University, Lund, Sweden.
Purpose: To compare treatment utilisation for osteoarthritis (OA) and satisfaction with OA management between individuals with and without comorbid metabolic conditions (e.g., diabetes, obesity, dyslipidaemia, hypertension).
View Article and Find Full Text PDFBMC Cancer
January 2025
Molecular Diseases & Diagnostics Division, Infinity Biochemistry, Infinity Solutions Unlimited, Sajjad Abad, Chattabal, Srinagar, 190010, Kashmir, India.
Background: Gynecological cancers (GCs) affect the reproductive system of females, and are of multiple types depending on the affected organ most common of which are cervical, endometrial, ovarian cancers. Among different risk factors for GCs, ABO blood group system is considered as one of the pivotal contributing factors for increased susceptibility of GCs. The aim of our study was to report on the demographics of GC patients and to investigate the relationship between the ABO blood group system and the risk of acquiring GC in our population.
View Article and Find Full Text PDFValue Health Reg Issues
January 2025
Novartis Singapore Pte Ltd, Singapore. Electronic address:
Objectives: This analysis evaluated the cost-effectiveness of inclisiran plus standard of care (SoC; comprising statins, ezetimibe, and fenofibrate) in primary hypercholesterolemia or mixed dyslipidemia from a Singapore healthcare system perspective. Inclisiran + SoC was separately compared with SoC, alirocumab + SoC, and evolocumab + SoC.
Methods: A lifetime Markov model in the United Kingdom (UK) was adapted to the Singapore setting.
JACC Adv
December 2024
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, New York, USA.
Background: The Hispanic/Latino population is not uniform. Prevalence and clinical outcomes of cardiac arrhythmias in ethnic background subgroups are variable, but the reasons for differences are unclear. Vectorcardiographic Global Electrical Heterogeneity (GEH) has been shown to be associated with adverse cardiovascular outcomes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!